- ArcDia to Expand Multianalyte Point-of-Care Respiratory Tract Diagnostic Test
Product News: ArcDia to Expand Multianalyte Point-of-Care Respiratory Tract Diagnostic TestArcDia Ltd has announced completion of a € 2.7 million funding round to expand its mariPOC® diagnostics system. The round was led by Lifeline Ventures, with the existing investors Biothom, Veraventure and private investors participating.
diagnoses nine common viruses and bacteria that are clinically important in respiratory tract infections, including influenza A/B, RS-virus and parainfluenza 1/2/3 viruses, in a single swab test at point-of-care. The test should enable targeted treatment decisions, save staff time, provide reliable results rapidly and be economically feasible for broad diagnostics use.
is based on the proprietary ArcDia™ TPX detection technology (Nature Biotech 2000:18). mariPOC®
was launched to the European market in late 2010, and the product has been in routine clinical use in major hospitals for more than a year. The first distribution agreement was signed in April with Laboratories Leti S.L.U., the Spanish market leader in diagnostic testing of pneumo-respiratory diseases.
“Simply, instead of performing multiple tests that take time to administer and diagnose, and may be difficult to read, mariPOC®
provides automated analysis for nine pathogens in one sample in 20 minutes - and with a clear, readable answer. No other diagnostics test platform has been able to provide this functionality and cost-effectiveness to enable respiratory tract infections testing at point-ofcare”, says Dr Aleksi Soini, CEO at ArcDia Ltd.
, point-of-care multianalyte diagnostic platforms have been too complicated, expensive, difficult-to-use and inaccurate for respiratory tract infections. mariPOC®
is taking into account clinical, economic and scientific matters to enable multianalyte diagnostics for this world’s most prevalent disease cluster”, comments Timo Ahopelto, Founding Partner at Lifeline Ventures.